BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy

Inhibition of Bruton’s Tyrosine Kinase (BTKi) is now viewed as a promising next-generation B-cell-targeting therapy for autoimmune diseases including multiple sclerosis (MS). Surprisingly little is known; however, about how BTKi influences MS disease-implicated functions of B cells. Here, we demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Rui, Tang, Hao, Burns, Jeremy C., Hopkins, Brian T., Le Coz, Carole, Zhang, Bo, de Barcelos, Isabella Peixoto, Romberg, Neil, Goldstein, Amy C., Banwell, Brenda L., Luning Prak, Eline T., Mingueneau, Michael, Bar-Or, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960592/
https://www.ncbi.nlm.nih.gov/pubmed/35303161
http://dx.doi.org/10.1007/s00401-022-02411-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960592/
https://www.ncbi.nlm.nih.gov/pubmed/35303161
http://dx.doi.org/10.1007/s00401-022-02411-w

Ejemplares similares